Breaking Bottlenecks Upstream in Radiopharmaceuticals | Reactors and Accelerators: Complementary, Not Competing ⚛️ As radiopharmaceuticals enter the multi-isotope era, one fundamental question become

2026-06-30

As radiopharmaceuticals enter the multi-isotope era, one fundamental question becomes increasingly important:

Where do medical isotopes come from?

Today, two major production routes support the medical isotope supply chain:

🏭 Reactor Production

Research reactors use high-flux neutrons to irradiate target materials, allowing atomic nuclei to capture neutrons and transform into radioactive isotopes.

This route is generally well suited for neutron-rich isotopes, such as Lu-177 and Mo-99, and for the large-scale supply of certain medium- and long-lived isotopes.

In simple terms: adding a neutron to the nucleus.

⚛️ Accelerator Production

Accelerators use charged particles — such as protons, deuterons, or alpha particles — to bombard target materials. Some routes also use electron beams to generate high-energy photons for photonuclear reactions.

This route is particularly important for neutron-deficient isotopes and for flexible, multi-isotope production.

Examples include F-18, C-11, N-13, Ga-68, Cu-64, Zr-89, I-124, Sc-44, At-211, and Ac-225.

In simple terms: using controlled particle bombardment to reshape the nucleus.

🧬 These two routes differ because they rely on different nuclear reaction mechanisms.

Reactors are well suited to certain neutron-rich isotopes. Accelerators provide important pathways for many diagnostic isotopes, emerging therapeutic isotopes, and multi-isotope R&D.

They are not substitutes for one another.

Instead, they support different isotope types, clinical needs, and supply scenarios:

🔹 Some isotopes are mainly reactor-produced

🔹 Some are better suited to accelerator production

🔹 Some can be supplied through both routes

🌍 In the multi-isotope era, the goal is not to rely on a single production method.

It is to build a more stable, flexible, and diversified isotope supply system.

Reactors and accelerators have different roles — and together, they form an essential foundation for the future medical isotope supply network.